Drug shows promise In reducing oral mucositis In patients with head and neck cancer

A new drug, GC4419 (Galera Therapeutics), may reduce a common side effect that occurs among 70 percent of patients with head and neck cancer who are being treated with radiotherapy – oral mucositis. Cancer treatments can break down rapidly dividing epithelial cells that line the gastrointestinal tract, which in turn, leaves the mucosal tissue open to ulceration or infection, also known as mucositis.
Cure Today